import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "semaglutide-side-effects-research-overview",
  title: "Semaglutide Side Effects: What the Clinical Trial Data Shows",
  description:
    "A data-driven review of semaglutide side effects from published clinical trials including STEP, SUSTAIN, and SELECT. GI adverse events, rare serious events, and what researchers need to know.",
  category: "GLP-1 Research",
  readMinutes: 10,
  publishedAt: "2026-06-10",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Semaglutide has been studied in some of the largest peptide-class clinical trials ever conducted, generating a substantial safety and adverse events database. Unlike most research peptides with limited human data, semaglutide's extensive clinical trial program (STEP 1-4, SUSTAIN 1-10, SELECT, FLOW) provides researchers with unusually robust safety information. This article synthesizes what that data shows.",
    },
    {
      type: "heading",
      text: "Most Common Adverse Events: The GI Profile",
    },
    {
      type: "paragraph",
      text: "Gastrointestinal adverse events are the most consistently documented side effects across semaglutide trials. These are mechanistically expected, as GLP-1 receptor agonism slows gastric emptying and modulates gut motility as part of its mechanism of action.",
    },
    {
      type: "subheading",
      text: "GI Adverse Event Frequency (STEP 1, Ozempic 2.4mg)",
    },
    {
      type: "list",
      text: "Nausea: 44% semaglutide vs 16% placebo — the most common adverse event across trials",
    },
    {
      type: "list",
      text: "Diarrhea: 30% semaglutide vs 16% placebo",
    },
    {
      type: "list",
      text: "Vomiting: 24% semaglutide vs 6% placebo",
    },
    {
      type: "list",
      text: "Constipation: 24% semaglutide vs 11% placebo",
    },
    {
      type: "list",
      text: "Abdominal pain: 20% semaglutide vs 10% placebo",
    },
    {
      type: "paragraph",
      text: "Critically, these events are predominantly mild-to-moderate and transient, peaking during dose-escalation phases and diminishing with continued exposure. Discontinuation due to GI adverse events occurred in approximately 4.5% of semaglutide-treated participants in STEP 1 vs 0.8% placebo.",
    },
    {
      type: "heading",
      text: "Serious Adverse Events of Special Interest",
    },
    {
      type: "subheading",
      text: "Pancreatitis",
    },
    {
      type: "paragraph",
      text: "Acute pancreatitis is a known concern class-wide for GLP-1 receptor agonists, stemming from pre-clinical data suggesting GLP-1R expression in pancreatic tissue. In STEP trials, the incidence of acute pancreatitis was 0.2% in semaglutide vs 0.1% placebo — a small but noted numerical difference. The SUSTAIN-6 cardiovascular outcomes trial reported similar rates. Current guidance from regulatory bodies does not establish a definitive causal link but flags pancreatitis as a risk to monitor in research studies involving GLP-1 agonists.",
    },
    {
      type: "subheading",
      text: "Thyroid C-Cell Effects",
    },
    {
      type: "paragraph",
      text: "Rodent carcinogenicity studies showed dose-dependent increases in thyroid C-cell tumors (medullary thyroid carcinoma) with semaglutide. This finding — consistent across GLP-1 receptor agonist class — has not been replicated in human clinical trials to date. In the large SELECT trial (17,604 participants, median follow-up 33 months), no significant increase in thyroid cancer was observed. The mechanism difference between rodents and humans regarding GLP-1R density in thyroid C-cells is considered the likely explanation, but long-term surveillance continues.",
    },
    {
      type: "subheading",
      text: "Gallbladder Events",
    },
    {
      type: "paragraph",
      text: "Rapid weight loss is independently associated with increased gallstone formation. In STEP trials, cholelithiasis occurred in 1.6% semaglutide vs 0.7% placebo, and cholecystitis in 0.6% vs 0.2%. These differences are consistent with weight-loss-driven effects rather than direct semaglutide pharmacology, though the distinction is difficult to establish in clinical research.",
    },
    {
      type: "subheading",
      text: "Heart Rate Elevation",
    },
    {
      type: "paragraph",
      text: "GLP-1 receptor agonists consistently produce a modest mean heart rate increase of approximately 2-5 bpm in clinical trials. The clinical significance of this finding in healthy populations is considered low, but researchers studying cardiovascular endpoints should include heart rate as a monitored parameter.",
    },
    {
      type: "heading",
      text: "Cardiovascular Safety: The SELECT Trial Data",
    },
    {
      type: "paragraph",
      text: "The SELECT trial (N=17,604, 2.4mg semaglutide weekly) was designed specifically to evaluate cardiovascular outcomes in patients with established cardiovascular disease without diabetes. It demonstrated a 20% relative risk reduction in MACE (major adverse cardiovascular events) compared to placebo. This positions semaglutide as cardioprotective in the studied population — a finding that reverses the cardiovascular safety concern that limited earlier diabetes drugs.",
    },
    {
      type: "heading",
      text: "Suicidality Signal Assessment",
    },
    {
      type: "paragraph",
      text: "Regulatory agencies conducted post-market safety reviews following reports of suicidal ideation in some GLP-1 agonist users. A 2024 FDA and EMA assessment found no causal relationship between semaglutide and suicidality, noting that several analyses showed either neutral or protective effects on mental health outcomes, possibly mediated by weight loss and metabolic improvement. Researchers studying behavioral endpoints should continue monitoring as data accumulates.",
    },
    {
      type: "heading",
      text: "Muscle Mass Concerns in Research Context",
    },
    {
      type: "paragraph",
      text: "DEXA scan data from STEP trials shows that approximately 30-40% of total weight lost on semaglutide is lean mass — consistent with any caloric restriction intervention. Researchers studying body composition endpoints should design studies that differentiate fat mass from lean mass outcomes and consider resistance training protocols in their study designs.",
    },
    {
      type: "heading",
      text: "Research-Grade Semaglutide: Purity and Source Considerations",
    },
    {
      type: "paragraph",
      text: "Researchers working with semaglutide must obtain compounds with verified purity (≥98% HPLC), documented endotoxin levels, and proper cold-chain storage. Semaglutide synthesis is technically demanding due to its size (molecular weight ~4,113 Da) and structural complexity; impurities from truncated or misfolded sequences can produce confounding biological signals in research studies.",
    },
    {
      type: "paragraph",
      text: "All compounds discussed in this article are intended for laboratory research use only. Not for human consumption. This article reviews published clinical trial data from pharmaceutical development programs; research peptide applications are distinct from pharmaceutical use.",
    },
  ],
};
